Viz.ai vs Lunit

Yes, Viz.ai has a higher valuation ($1.2B) compared to Lunit ($829M).

Viz.ai raised $289M while Lunit raised $150M.

Viz.ai has the higher Awaira Score of 66.

Viz.ai: Viz.ai is an artificial intelligence healthcare company founded in 2016 that develops clinical decision support software for medical imaging analysis. The company specializes in AI-powered diagnostic tools that assist radiologists and emergency physicians in identifying acute neurological and cardiovascular conditions from medical imaging scans. Viz.ai's core platform uses deep learning algorithms to detect conditions such as stroke, pulmonary embolism, and aortic dissection, prioritizing urgent cases and flagging them for immediate physician review. The company's primary products include stroke detection software and platforms for identifying other time-critical conditions in emergency departments. Viz.ai operates within the broader clinical AI segment, competing with companies developing similar diagnostic imaging solutions. The platform integrates into existing hospital workflows and imaging infrastructure, providing real-time alerts to clinicians. Viz.ai has achieved significant market validation, with its technology adopted across numerous healthcare systems in the United States. The company raised Series D funding at a $1.2 billion valuation, reflecting investor confidence in the clinical AI market. Total funding reached $289 million across multiple rounds. The company's growth trajectory demonstrates expanded adoption among major hospital networks and healthcare providers seeking to improve diagnostic speed and clinical outcomes for emergency conditions. Viz.ai focuses specifically on time-critical emergency conditions where AI-assisted early detection directly impacts patient outcomes and hospital operations.. Lunit: Lunit is a South Korean AI healthcare company founded in 2013 that specializes in diagnostic imaging analysis using artificial intelligence. The company develops machine learning algorithms designed to assist radiologists in detecting abnormalities across medical imaging modalities, particularly in chest radiography, breast cancer screening, and CT scans. Lunit's core platform uses deep learning to analyze medical images and provide clinical decision support, aiming to improve diagnostic accuracy and efficiency in healthcare settings. The company's primary products include Lunit INSIGHT, a software solution that integrates with existing hospital infrastructure and picture archiving systems. Lunit has established a presence across Asia, Europe, and other regions, with its technology deployed in hospitals and diagnostic centers. The company went public on the Korean stock exchange, achieving a valuation of $0.8 billion. With $150 million in total funding raised through various rounds before its public listing, Lunit operates in a competitive segment alongside companies like Zebra Medical Vision, Arterys, and various regional competitors. The company faces competition from both specialized AI diagnostic firms and larger healthcare technology providers developing similar capabilities. Lunit's growth trajectory reflects increasing adoption of AI in medical imaging across Asia-Pacific markets, where regulatory pathways and healthcare infrastructure continue to evolve to accommodate such technologies. Lunit is among the few AI medical imaging companies to achieve public market status, particularly from South Korea, reflecting regional strength in healthcare technology innovation..

Lunit was founded first in 2013. Viz.ai was founded in 2016.